文献速递骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤妇科肿瘤

Lifirafenib(BGB-283)治疗实体瘤的I期剂量递增/扩展研究

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
PubMed 文献 · J Clin Oncol · 2020-03-17

该首个人体I期剂量递增/扩展研究评估了RAF家族激酶及EGFR抑制剂lifirafenib在B-RAF或K-RAS/N-RAS突变实体瘤患者中的安全性、耐受性和疗效。最大耐受剂量为40 mg/d,总体风险获益可接受,在B-RAFV600突变黑色素瘤、甲状腺癌和低级别浆液性卵巢癌及K-RAS突变非小细胞肺癌和子宫内膜癌中观察到抗肿瘤活性。

要点

  • 最大耐受剂量为40 mg/d,剂量限制性毒性包括可逆性血小板减少和非血液学毒性。
  • B-RAFV600E/K黑色素瘤、甲状腺癌和低级别浆液性卵巢癌中观察到客观缓解。
  • K-RAS突变结直肠癌患者(n=20)未见缓解。

核心结论

  • Lifirafenib具有可接受的风险获益特征,在B-RAFV600突变实体瘤及部分K-RAS突变肿瘤中显示抗肿瘤活性。

研究设计与样本

  • 首个人体、开放标签、I期剂量递增/剂量扩展研究,纳入组织学/细胞学确认的晚期实体瘤成人患者。

主要发现

  • 最大耐受剂量为40 mg/d,剂量限制性毒性包括可逆性血小板减少和非血液学毒性。
  • 全程最常见≥3级治疗出现的不良事件为高血压(n=23;17.6%)和疲乏(n=13;9.9%)。
  • 1例B-RAF突变黑色素瘤患者达完全缓解,8例B-RAF突变患者确认客观缓解:B-RAFV600E/K黑色素瘤(n=5,含1例既往接受过B-RAF/MEK抑制剂治疗)、B-RAFV600E甲状腺癌/甲状腺乳头状癌(n=2)、B-RAFV600E低级别浆液性卵巢癌(n=1)。
  • 1例B-RAF突变非小细胞肺癌患者达未确认部分缓解。
  • K-RAS突变子宫内膜癌和K-RAS第12密码子突变非小细胞肺癌各1例确认部分缓解;K-RAS/N-RAS突变结直肠癌患者(n=20)未见缓解。

临床怎么用

  • 对于B-RAFV600突变黑色素瘤、甲状腺乳头状癌和低级别浆液性卵巢癌,lifirafenib显示初步抗肿瘤活性。
  • K-RAS突变非小细胞肺癌和子宫内膜癌中观察到部分缓解,但K-RAS突变结直肠癌未见缓解。
  • 未来需与第一代B-RAF抑制剂比较,并探索单药或联合治疗用于对第一代B-RAF抑制剂耐药/难治的选择性RAS突变患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib in patients with B-RAF- or K-RAS/N-RAS-mutated solid tumors. METHODS: During dose escalation, adult patients with histologically/cytologically confirmed advanced solid tumors received escalating doses of lifirafenib. Primary end points were safety/tolerability during dose escalation and objective response rate in preselected patients with B-RAF and K-RAS/N-RAS mutations during dose expansion. RESULTS: The maximum tolerated dose was established as 40 mg/d; dose-limiting toxicities included reversible thrombocytopenia and nonhematologic toxicity. Across the entire study, the most common grade ≥ 3 treatment-emergent adverse events were hypertension (n = 23; 17.6%) and fatigue (n = 13; 9.9%). One patient with B-RAF-mutated melanoma achieved complete response, and 8 patients with B-RAF mutations had confirmed objective responses: B-RAFV600E/K melanoma (n = 5, including 1 patient treated with prior B-RAF/MEK inhibitor therapy), B-RAFV600E thyroid cancer/papillary thyroid cancer (PTC; n = 2), and B-RAFV600E low-grade serous ovarian cancer (LGSOC; n = 1). One patient with B-RAF-mutated non-small-cell lung cancer (NSCLC) had unconfirmed partial response (PR). Patients with K-RAS-mutated endometrial cancer and K-RAS codon 12-mutated NSCLC had confirmed PR (n = 1 each). No responses were seen in patients with K-RAS/N-RAS-mutated colorectal cancer (n = 20). CONCLUSION: Lifirafenib is a novel inhibitor of key RAF family kinases and EGFR, with an acceptable risk-benefit profile and antitumor activity in patients with B-RAFV600-mutated solid tumors, including melanoma, PTC, and LGSOC, as well as K-RAS-mutated NSCLC and endometrial carcinoma. Future comparisons with first-generation B-RAF inhibitors and exploration of lifirafenib alone or as combination therapy in patients with selected RAS mutations who are resistant/refractory to first-generation B-RAF inhibitors are warranted.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Desai J, Gan H, Barrow C, et al. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. J Clin Oncol. 2020. PMID: 32182156. doi:10.1200/JCO.19.02654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。